Intas Pharmaceuticals Limited — Oxaliplatin Exporter Profile
Indian Pharmaceutical Exporter · #10 for Oxaliplatin · $790.8K export value · DGFT Verified
Intas Pharmaceuticals Limited is the #10 Indian exporter of Oxaliplatin with $790.8K in export value and 32 verified shipments. Intas Pharmaceuticals Limited holds a 1.7% market share in Oxaliplatin exports across 6 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Oxaliplatin Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Oxaliplatin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| BRAZIL | $459.3K | 13 | 53.5% |
| NETHERLANDS | $128.9K | 6 | 15.0% |
| PHILIPPINES | $72.5K | 10 | 8.5% |
| FRANCE | $50.0K | 1 | 5.8% |
| UNITED KINGDOM | $46.2K | 1 | 5.4% |
| SOUTH AFRICA | $42.6K | 3 | 5.0% |
| UNITED STATES OF AMERICA | $36.5K | 1 | 4.3% |
| POLAND | $10.8K | 2 | 1.3% |
| SPAIN | $10.3K | 1 | 1.2% |
| ITALY | $785 | 9 | 0.1% |
Intas Pharmaceuticals Limited exports Oxaliplatin to 10 countries. The largest destination is BRAZIL accounting for 53.5% of Intas Pharmaceuticals Limited's Oxaliplatin shipments, followed by NETHERLANDS (15.0%) and PHILIPPINES (8.5%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Oxaliplatin from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER | BRAZIL | $162.3K | 5 |
| ACCORD FARMACUTICA LTDA. | BRAZIL | $146.7K | 4 |
| ACCORD FARMACUTICA LTDA | BRAZIL | $114.8K | 3 |
| XXCORXXHEAXXHCAXX B XX | FRANCE | $100.0K | 2 |
| ACCORD HEALTHCARE B V | NETHERLANDS | $76.6K | 4 |
| ACCORD HEALTHCARE LTD | ITALY | $46.7K | 7 |
| ASIA UNITED BANK CORPORATION | PHILIPPINES | $42.4K | 4 |
| XXCORXXHEAXXHCAXX INXX | UNITED STATES OF AMERICA | $36.5K | 1 |
| ACCORD FARMACUTICA LIMITEDA | BRAZIL | $35.6K | 1 |
| ACCORD HEALTHCARE C O QESTMED PTY | SOUTH AFRICA | $33.8K | 1 |
Intas Pharmaceuticals Limited supplies Oxaliplatin to 20 buyers globally. The largest buyer is TO THE ORDER (BRAZIL), followed by ACCORD FARMACUTICA LTDA. (BRAZIL) and ACCORD FARMACUTICA LTDA (BRAZIL). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Oxaliplatin Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $32.6M worth of Oxaliplatin through 3,081 shipments from 249 suppliers to 123 countries, serving 693 buyers globally. Intas Pharmaceuticals Limited contributes $790.8K to this total, accounting for 1.7% of India's Oxaliplatin exports. Intas Pharmaceuticals Limited ships Oxaliplatin to 10 countries through 20 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Oxaliplatin Exports?
Intas Pharmaceuticals Limited's average Oxaliplatin shipment value is $24.7K per consignment, based on 32 shipments totaling $790.8K. The largest destination is BRAZIL (53.5% of Intas Pharmaceuticals Limited's Oxaliplatin exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Oxaliplatin Exporters?
Intas Pharmaceuticals Limited ranks #10 among 249 Indian Oxaliplatin exporters with a 1.7% market share. The top 3 exporters are FRESENIUS KABI ONCOLOGY LIMITED ($16.6M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($3.6M), ACCURE LABS PRIVATE LIMITED ($2.6M). Intas Pharmaceuticals Limited processed 32 shipments to 6 destination countries.
What Oxaliplatin Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARM DRUG&MED OXA OXALIPLATIN 5MG/ML,40ML 1V (ACC-BR) EACH ML CONTAINS: OXALIPLATIN PH.EUR 5 MG | $91.2K | 3 |
| PHARMACEUTICAL DRUGS AND MEDICINE - OXAOXALIPLATIN 5MG/ML,20ML 1V (ACC-BR) ASAPER INVOICE | $62.4K | 2 |
| OXALIPLATINLF5MG/ML,10MLACO-FRANCE | $50.2K | 2 |
| PHARMA DRUGS & MEDI OXA OXALIPLATIN 5MG/ | $50.0K | 1 |
| PHARMA DRUGS AND MEDI OXA OXALIPLATIN 5MG/ML,20ML 1V ACC-BR AS PER INV | $50.0K | 1 |
| OXALIPLATINLF5MG/ML40MLACO-GERMANY | $50.0K | 1 |
| OXALIPLATIN(LF)5MG/ML 40ML(ACO-GERMANY | $50.0K | 1 |
| OXALIPLATINLF 5MG/ML,10MLACCORD-UK | $46.3K | 2 |
| OXALIPLATIN INJ 5MG/ML 10ML 1X1V | $36.5K | 1 |
| PHARMA DRUGS AND MEDICINE OXA OXALIPLATIN 5MG ML 20ML 1V ACC BR Each mL contains QTY 6720X1X1VIAL AS PER INV | $36.1K | 1 |
Intas Pharmaceuticals Limited exports 34 distinct Oxaliplatin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARM DRUG&MED OXA OXALIPLATIN 5MG/ML,40ML 1V (ACC-BR) EACH with 3 shipments worth $91.2K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Oxaliplatin to Key Markets
What Intas Pharmaceuticals Limited must comply with to export Oxaliplatin to its top destination countries
Brazil — ANVISA
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Intas Pharmaceuticals Limited Compare to Nearest Oxaliplatin Exporters?
Exporters ranked immediately above and below #10 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | GLAND PHARMA LIMITED | $1.0M | 20 | 1 | $50.0K |
| 9 | ZYDUS HOSPIRA ONCOLOGY PRIVATE LIMITED | $850.0K | 17 | 10 | $50.0K |
| 10 | INTAS PHARMACEUTICALS LIMITED ★ | $790.8K | 32 | 6 | $24.7K |
| 11 | NV REMEDIES PRIVATE LIMITED | $651.6K | 16 | 4 | $40.7K |
| 6 | MYLAN LABORATORIES LIMITED | $600.0K | 12 | 1 | $50.0K |
Intas Pharmaceuticals Limited ranks #10 among 249 Indian Oxaliplatin exporters. Average shipment value of $24.7K compared to the market average of $130.9K. The closest competitors by value are GLAND PHARMA LIMITED and ZYDUS HOSPIRA ONCOLOGY PRIVATE LIMITED.
Which Indian Ports Ship Oxaliplatin Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 535 | 17.4% |
| SAHAR AIR CARGO ACC (INBOM4) | 453 | 14.7% |
| DELHI AIR | 436 | 14.2% |
| SAHAR AIR | 410 | 13.3% |
| CHAWAPAYAL ICD (INCPR6) | 110 | 3.6% |
| Bombay Air | 108 | 3.5% |
| NHAVA SHEVA SEA (INNSA1) | 97 | 3.1% |
| CHAWAPAYAL ICD | 95 | 3.1% |
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Oxaliplatin Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Oxaliplatin, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Oxaliplatin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Oxaliplatin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 47 individual customs records matching Intas Pharmaceuticals Limited exporting Oxaliplatin, covering 34 formulations to 10 countries via 20 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 123+ countries, 693+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Oxaliplatin Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Oxaliplatin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Oxaliplatin Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Oxaliplatin. For current shipment-level data, contact TransData Nexus.